PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 61 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,709,601 | -31.3% | 10,909,256 | 0.0% | 0.72% | -19.6% |
Q2 2023 | $49,091,652 | -14.2% | 10,909,256 | +8.7% | 0.89% | -20.7% |
Q1 2023 | $57,226,239 | -5.6% | 10,039,691 | 0.0% | 1.12% | -3.2% |
Q4 2022 | $60,639,734 | -8.6% | 10,039,691 | 0.0% | 1.16% | -5.8% |
Q3 2022 | $66,362,000 | +26.6% | 10,039,691 | 0.0% | 1.23% | +29.7% |
Q2 2022 | $52,407,000 | -24.3% | 10,039,691 | 0.0% | 0.95% | -15.4% |
Q1 2022 | $69,274,000 | -44.6% | 10,039,691 | 0.0% | 1.12% | -30.1% |
Q4 2021 | $124,994,000 | -60.2% | 10,039,691 | 0.0% | 1.61% | -53.4% |
Q3 2021 | $313,740,000 | +9.2% | 10,039,691 | 0.0% | 3.45% | +18.6% |
Q2 2021 | $287,436,000 | -33.9% | 10,039,691 | 0.0% | 2.91% | -28.5% |
Q1 2021 | $435,020,000 | -61.0% | 10,039,691 | -35.6% | 4.07% | -58.3% |
Q4 2020 | $1,115,813,000 | +137.5% | 15,594,877 | 0.0% | 9.76% | +65.3% |
Q3 2020 | $469,874,000 | – | 15,594,877 | – | 5.91% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Orbimed Advisors | 10,909,256 | $33,709,601 | 0.72% |
Boxer Capital, LLC | 2,495,018 | $7,709,606 | 0.41% |
Sio Capital Management, LLC | 350,000 | $1,081,500 | 0.34% |
Baker Brothers Advisors | 10,123,824 | $31,282,616 | 0.18% |
EcoR1 Capital, LLC | 1,157,452 | $3,576,527 | 0.12% |
GSA CAPITAL PARTNERS LLP | 70,583 | $218 | 0.02% |
Pale Fire Capital SE | 30,781 | $95,113 | 0.01% |
Woodline Partners LP | 200,000 | $618,000 | 0.01% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 143,957 | $444,827 | 0.00% |
EXCHANGE TRADED CONCEPTS, LLC | 32,907 | $101,683 | 0.00% |